In recent years, significant progress has been made in the treatment of management in heart failure, with the use of SGLT2 inhibitors being an important discovery in treatment (Zinman et al., 2015a; Neal et al., 2017a; Wiviott et al., 2019a; McMurray et al., 2019; Packer et al., 2020; Anker et al., 2021; Solomon et al., 2022). The gene discussed is SLC5A2; the disease is heart failure.